24632-70-0

Basic information

• Product Name: 1-Piperazineaceticacid, 4-(phenylmethyl)-, hydrazide
• Synonyms: 1-Piperazineaceticacid, 4-(phenylmethyl)-, hydrazide;2-(4-BENZYLPIPERAZIN-1-YL)ACETOHYDRAZIDE;4-(Phenylmethyl)-1-piperazineacetic acid;4-Benzyl-1-piperazineacetic acid;4-(Phenylmethyl)-1-piperazineacetic acid,hydrazide;2-(4-benzylpiperazin-1-yl)acetic acid;4-Benzyl-1-piperazineacetic Acid Hydrazide
• CAS NO: 24632-70-0
• Molecular Formula: C₁₃H₂₀N₄O
• Molecular Weight: 248.3241
• Product Categories: Aromatics, Heterocycles, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 24632-70-0.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 443.496 °C at 760 mmHg
• Flash Point: 222.019 °C
• Appearance: /
• Density: 1.16 g/cm³
• Vapor Pressure: 1.33E-06mmHg at 25°C
• Refractive Index: 1.573
• PKA: 13.37±0.37(Predicted)
• CAS DataBase Reference: 1-Piperazineaceticacid, 4-(phenylmethyl)-, hydrazide(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperazineaceticacid, 4-(phenylmethyl)-, hydrazide(24632-70-0)
• EPA Substance Registry System: 1-Piperazineaceticacid, 4-(phenylmethyl)-, hydrazide(24632-70-0)

Safety Data

• Hazardous Substances Data: 24632-70-0(Hazardous Substances Data)

Usage

Uses

4-Benzyl-1-piperazineacetic Acid Hydrazide is an intermediate in the synthesis PAC-1 (P132000), a caspase 3 activator.

InChI:InChI=1/C13H18N2O2/c16-13(17)11-15-8-6-14(7-9-15)10-12-4-2-1-3-5-12/h1-5H,6-11H2,(H,16,17)

Upstream product

• 23173-76-4 ethyl 2-(4-benzylpiperazin-1-yl)acetate 
• 40004-08-8 1-(Ethoxycarbonylmethyl)piperazine 
• 100-44-7 benzyl chloride 
• 2759-28-6 1-phenylmethylpiperazine 

Downstream Products

• 315183-08-5 de-allyl PAC-1 
• 315183-21-2 2-(4-benzylpiperazin-1-yl)-N-[(2-hydroxy-3-prop-2-enylphenyl)methylideneamino]acetamide 
• 1075725-57-3 N'-(3-allyl-2-methoxybenzylidene)-2-(4-benzylpiperazin-1-yl)acetohydrazide 
• 1075725-59-5 C₂₀H₂₃N₇O₂ 
• 1075725-60-8 2-(4-benzylpiperazin-1-yl)-N'-(3,5-diallyl-2-hydroxybenzylidene)acetohydrazide 
• 315183-07-4 N'-(4-methoxybenzylidene)-2-(4-benzylpiperazin-1-yl)acetohydrazide 
• 315182-88-8 N'-(4-ethoxybenzylidene)-2-(4-benzylpiperazin-1-yl)acetohydrazide 
• 303106-00-5 N'-(3,4-dimethoxybenzylidene)-2-(4-benzylpiperazin-1-yl)acetohydrazide 
• 1554476-27-5 N′-[(5-fluoro-2-hydroxy-3-propylphenyl)methylene]-4-(phenylmethyl)-1-piperazineacetohydrazide 
• 1554476-07-1 N′-[[5-fluoro-2-hydroxy-3-(2-propenyl)phenyl]methylene]-4-(phenylmethyl)-1-piperazineacetohydrazide 
• 1449679-58-6 2-(4-benzylpiperazin-1-yl)-N'-(2-(bis(pyridin-2-ylmethyl)amino)acetyl)acetohydrazide 
• 1449679-59-7 (E)-2-(4-benzylpiperazin-1-yl)-N'-((3-hydroxy-5-(hydroxymethyl)-2-methylpyridin-4-yl)methylene)acetohydrazide 
• 315183-20-1 C₂₁H₂₆N₄O₂ 
• 315183-06-3 (4-((4-(2-(2-(3-allyl-2-hydroxybenzylidene)hydrazinyl)-2-oxoethyl)piperazin-1-yl)methyl)benzenesulfonamide) 

Relevant articles and documents

Synthesis and initial in vitro biological evaluation of two new zinc-chelating compounds: Comparison with TPEN and PAC-1

The lipophilic, cell-penetrating zinc chelator N,N,N′,N′,- tetrakis(2-pyridylmethyl) ethylenediamine (TPEN, 1) and the zinc chelating procaspase-activating compound PAC-1 (2) both have been reported to induce apoptosis in various cell types. The relations

DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS

Compositions and methods are disclosed in embodiments relating to induction of cell death such as in cancer cells. Compounds and related methods for synthesis and use thereof, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds are disclosed that have lower neurotoxicity effects than other compounds.

SELECTIVE APOPTOTIC INDUCTION IN CANCER CELLS INCLUDING ACTIVATION OF PROCASPASE-3

Compounds and related methods for synthesis, and the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds are disclosed in connection with modification of procaspases such as procaspase-3, and particular embodiments are capable of direct activation of procaspase-3 and procaspase-7 to the effector forms of caspase-3 and caspase-7. Procaspase-3 levels can vary among cancer cell types; several types have relatively high levels and can have increased susceptibility to chemotherapy by compounds and methods herein. Therapeutic applications are relevant for a variety of cancer conditions and cell types, e.g. breast, lung, brain, colon, renal, adrenal, melanoma, and others.